Technical analysis of Belite Bio, Inc (BLTE): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily.
Price Performance
| 1 month | -1.03% |
| 3 months | -5.54% |
| Year-to-date | -3.72% |
| 1 year | +37.00% |
| 3 years | +292.58% |
52-Week Range
| 52-week High | $200.00 |
| 52-week Low | $102.00 |
| Avg Volume (90d) | 174K |
Technical Indicators
| SMA 50 | $161.04 |
| SMA 200 | $160.34 |
| Beta | -1.22 |
| 30-day Volatility (annualised) | 38.3% |
| Price vs SMA 50 | -4.4% |
| Price vs SMA 200 | -3.9% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $159.96 | |
| 2026-01 | $169.00 | +5.7% |
| 2026-02 | $190.30 | +12.6% |
| 2026-03 | $159.44 | -16.2% |
| 2026-04 | $159.16 | -0.2% |
| 2026-05 | $144.18 | -9.4% |
| 2026-06 | $153.99 | +6.8% |
| 2026-07 | $158.61 | +3.0% |
| 2026-08 | $155.71 | -1.8% |
| 2026-09 | $169.82 | +9.1% |
| 2026-10 | $154.74 | -8.9% |
| 2026-11 | $154.01 | -0.5% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-09 | $-0.79 | |
| 2026-08-12 | $-0.73 | |
| 2026-05-20 | $-0.60 | |
| 2026-03-02 | $-0.56 | $17M |
| 2025-11-10 | $-0.53 | |
| 2025-08-11 | $-0.47 | |
| 2025-05-13 | $-0.36 | |
Price
| Price | $154.01 (closing price, November 4, 2026) |
| Market Cap | $6.2B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 7.97 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 33.56 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 319.70 |